<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547504</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC20.0159_GFPC01-2020</org_study_id>
    <secondary_id>GFPC 01-2020</secondary_id>
    <nct_id>NCT04547504</nct_id>
  </id_info>
  <brief_title>PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %</brief_title>
  <acronym>PERSEE</acronym>
  <official_title>Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Français de Pneumo-Cancérologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab&#xD;
      combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly&#xD;
      defined by a PDL1 expression ≥ 50% of tumour cells and no EGFR mutations or ALK&#xD;
      rearrangement.&#xD;
&#xD;
      The main hypothesis is the superiority of the chemo-immunotherapy combination over&#xD;
      mono-immunotherapy in terms of progression-free survival evaluated by an independent review&#xD;
      committee.&#xD;
&#xD;
      One of the anticipated benefits of using the chemotherapy-pembrolizumab combination starting&#xD;
      from the first line setting for NSCLC patients with PD L1 ≥ 50% is a reduced risk of early&#xD;
      progression, which is known to occur with pembrolizumab monotherapy, and therefore, a better&#xD;
      PFS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PERSEE is a french academic, prospective, randomized, controlled and open-label phase 3&#xD;
      study. This trial compares the combination of chemotherapy and pembrolizumab with&#xD;
      pembrolizumab alone as first-line treatment for advanced NSCLC molecularly characterized by a&#xD;
      PDL1 expression level ≥ 50% and no EGFR mutations or ALK rearrangement. This is a strategy&#xD;
      trial whose primary objective is to evaluate the superiority of the&#xD;
      chemotherapy-pembrolizumab combination over pembrolizumab using PFS as the primary endpoint&#xD;
      as evaluated by an independent review committee.&#xD;
&#xD;
      PERSEE trial is planned to include 292 patients treated at approximately 30 GFPC-affiliated&#xD;
      or GFPC-associated centres. After the screening period, patients will be randomized on a 1:1&#xD;
      basis to the Chemotherapy Immunotherapy Arm or the Immunotherapy Arm. Randomization will be&#xD;
      stratified according to tumor histology (squamous versus non squamous) and according to the&#xD;
      presence or absence of brain metastases. Patients enrolled in this study will receive either&#xD;
      of the following treatment regimens:&#xD;
&#xD;
        1. Chemotherapy-Immunotherapy Arm:&#xD;
&#xD;
           Four induction cycles once every 3 weeks associating, on the first day of each cycle:&#xD;
&#xD;
             -  Cisplatin 75 mg/m² or carboplatin area under the curve (AUC) 5 mg/mL/min,&#xD;
                pemetrexed 500 mg/m² and pembrolizumab 200 mg for non-squamous NSCLC.&#xD;
&#xD;
             -  Carboplatin AUC 6 mg/mL/min, paclitaxel 200 mg/m² and pembrolizumab 200 mg for&#xD;
                squamous NSCLC.&#xD;
&#xD;
           After the 4 induction cycles, a maintenance therapy will be possible for patients who&#xD;
           are responding or stable, as follows:&#xD;
&#xD;
             -  Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as&#xD;
                monotherapy (if toxicity has been identified for one of them).&#xD;
&#xD;
             -  Squamous NSCLC: pembrolizumab monotherapy.&#xD;
&#xD;
           For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until&#xD;
           disease progression, death, unacceptable toxicity, or following the Investigator's or&#xD;
           the patient's decision to stop.&#xD;
&#xD;
           For pemetrexed, treatment may be continued until disease progression, death,&#xD;
           unacceptable toxicity, or following the Investigator's or the patient's decision to&#xD;
           stop.&#xD;
&#xD;
        2. Immunotherapy Arm:&#xD;
&#xD;
      Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease&#xD;
      progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to&#xD;
      stop.&#xD;
&#xD;
      Evaluations will be performed every 6 weeks (±7 days) during the first 4 cycles in both&#xD;
      treatment arms, then every 9 weeks (±7 days) for the first 12 months since D1 of cycle 1 and&#xD;
      every 12 weeks (±7 days) thereafter.&#xD;
&#xD;
      Evaluations will include: tumor assessment according to RECIST v1.1, survival status,&#xD;
      concomitant medications and AE recording. QoL/PRO questionnaires will be performed at each&#xD;
      cycle for the first 5 cycles in both treatment arms, then every 9 weeks (±7 days) for the&#xD;
      first 12 months since D1 of cycle 1 and every 12 weeks (±7 days) thereafter.&#xD;
&#xD;
      The length of the inclusion period is 36 months (3 years). The total study duration per&#xD;
      patient will be a maximum of two years for the last patients included, and a maximum of five&#xD;
      years for the first patients included (i.e. End-of-study Time Point for surviving patients)&#xD;
&#xD;
      The total study duration includes the following:&#xD;
&#xD;
        -  Screening Period: up to 28 days.&#xD;
&#xD;
        -  Treatment Period: up to 60 months.&#xD;
&#xD;
        -  Post-study Follow up Period: until death or lost to follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A national, multicenter, phase III, prospective, open label, 1:1 randomized, interventional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, according to RECIST 1.1 assessed by blinded inependant centra review (BICR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival according to RECIST 1.1 evaluated by investigators</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of randomization until the date of first documented progression or death from any cause, whichever came first, according to RECIST v1.1 and evaluated by investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival according to iRECIST assessed by blinded inependant centra review (BICR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first assessed up to 60 months</time_frame>
    <description>Time from date of randomization until the date of first documented progression or death from any cause, whichever came first, according to iRECIST assessed by blinded inependant centra review (BICR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From date of first treatment administration until the date of first documented progression or death or the introduction of a new treatment, whichever came first, assessed up to 60 months</time_frame>
    <description>Proportion of patients who achieved a complete response (CR) or partial response (PR) according to RECIST v1.1 from the date of first treatment administration until disease progression or the introduction of a new treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 60 months</time_frame>
    <description>Time from date of randomization until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment (DOT)</measure>
    <time_frame>From date of the first treatment administration until the date of last treatment administration, up to 60 months</time_frame>
    <description>Time from the first treatment administration until the date of last treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (DOR)</measure>
    <time_frame>From date of the first documented objective response (CR or PR) until the date of first documented progression or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from the first documented objective response (CR or PR) until the date of disease progression or death, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Up to 30 days after the last dose of study treatment for non-serious AEs. Up to 100 days or 30 days if initiating new treatment, after the last dose, for SAE.</time_frame>
    <description>Proportion (%) of patients with any adverse event (AE) and number of events per treatment arm for all AEs, all serious AEs (SAEs) and all AEs of grade ≥3 according to the National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) v5.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of special interest (AESI)</measure>
    <time_frame>Up to 100 days or 30 days if initiating new treatment, after the last dose.</time_frame>
    <description>Proportion (%) of patients with any adverse event of special interest (AESI), defined as immune-related AE (IrAE), according to the National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) v5.0 criteria. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>From date of randomization until the date of first documented progression or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from date of randomization until the date of first documented progression or death from any cause, whichever came first, according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 60 months</time_frame>
    <description>Time from randomization until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>From date of first treatment administration until the date of first documented progression or death or the introduction of a new treatment, whichever came first, assessed up to 60 months</time_frame>
    <description>Proportion of patients who achieved a complete response (CR) or partial response (PR) according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>From date of the first documented objective response (CR or PR) until the date of first documented progression or death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time from the first documented objective response (CR or PR) until the date of disease progression or death, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOT in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>From date of the first treatment administration until the date of last treatment administration, assessed up to 60 months</time_frame>
    <description>Time from the first treatment administration until the date of last treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>Up to 30 days after the last dose of study treatment for non-serious AEs. Up to 100 days or 30 days if initiating new treatment, after the last dose, for SAE.</time_frame>
    <description>Proportion (%) of patients with any adverse event (AE) and number of events per treatment arm for all AEs, all serious AEs (SAEs) and all AEs of grade ≥3 according to the National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) v5.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AESI in three subgroups of patients according to PD-L1 expression (50-74%, 75-100%, and 90-100%), presence or absence of brain metastasis and histology (squamous versus non squamous).</measure>
    <time_frame>Up to 100 days or 30 days if initiating new treatment, after the last dose.</time_frame>
    <description>Proportion (%) of patients with any adverse event (AE) and number of events per treatment arm for all AEs, all serious AEs (SAEs) and all AEs of grade ≥3 according to the National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) v5.0 criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Early progression rate</measure>
    <time_frame>Up to 6 weeks from the first day of treatment</time_frame>
    <description>proportion of patients with clinical and/or radiological tumor progression according to RECIST v1.1 before or at the first radiological evaluation at 6 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Following of the quality of life with European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Cancer patients.</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire with 30 questions developed to assess the quality of life of cancer patients.&#xD;
An essential aspect of the &quot;modular&quot; approach to QOL assessment adopted by the EORTC Quality of Life Group is the development of modules specific to tumour site, treatment modality, or a QOL dimension, to be administered in addition to the core questionnaire (EORTC QLQ-C30). Mini: 42. Maxi: 114. Hisher score mean worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Following of the quality of life with European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Lung Cancer patients.</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>The EORTC Study Group on Quality of Life has developed a modular system for assessing the quality of life of cancer patients in clinical trials composed of two basic elements: (1) a core quality of life questionnaire, the EORTC QLQ-C30, covering general aspects of health-related quality of life, and (2) additional disease- or treatment-specific questionnaire modules. Two international field studies were carried out to evaluate the practicality, reliability and validity of the core questionnaire, supplemented by a 13-item lung cancer-specific questionnaire module, the EORTC QLQ-LC13.The lung cancer questionnaire module comprises both multi-item and single-item measures of lung cancer associated symptoms (i.e. coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (i.e. hair loss, neuropathy, sore mouth and dysphagia). Mini: 13. Maxi: 52. Higher score means worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Following of the quality of life with European Quality of life 5 dimensions and 3 Levels</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Mini: 0. Maxi: 100. Higher score means better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory analyses to identify novel biomarkers</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 60 months</time_frame>
    <description>Blood and tissue analyses to identify novel biomarkers of efficacy and resistance.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy-Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy and Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab and Chemotherapy drugs</intervention_name>
    <description>An induction therapy followed by a maintenance therapy.&#xD;
4 induction cycles every 3 weeks associating, on the first day of each cycle:&#xD;
Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.&#xD;
Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.&#xD;
After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:&#xD;
Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.&#xD;
Squamous NSCLC: pembrolizumab monotherapy.&#xD;
For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.&#xD;
For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.</description>
    <arm_group_label>Chemotherapy-Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older at diagnosis.&#xD;
&#xD;
          2. Histologically or cytologically confirmed NSCLC.&#xD;
&#xD;
          3. Stage IV NSCLC. Unresectable and non-eligible to radiotherapy stage III NSCLC are&#xD;
             permitted.&#xD;
&#xD;
          4. For non-squamous NSCLCs and non-smoking squamous NSCLCs, no known activating mutations&#xD;
             of EGFR and no ALK or ROS-1 rearrangements.&#xD;
&#xD;
          5. PD-L1 expression on ≥ 50 % of tumor cells, which will be determined locally.&#xD;
&#xD;
          6. No prior systemic treatment for lung cancer. Patients who received adjuvant therapy&#xD;
             are eligible if the adjuvant therapy was completed at least 12 months prior to the&#xD;
             development of metastatic disease.&#xD;
&#xD;
          7. Palliative radiotherapy completed within one day before randomization (stereotaxic or&#xD;
             not) is authorized.&#xD;
&#xD;
          8. At least 1 target lesion in a non-irradiated area, measurable according to RECIST&#xD;
             v1.1.&#xD;
&#xD;
          9. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.&#xD;
&#xD;
         10. Life expectancy &gt;12 weeks.&#xD;
&#xD;
         11. Patients with brain metastases at inclusion are accepted, provided that these&#xD;
             metastases are asymptomatic, or symptomatic but treated (surgery or radiotherapy&#xD;
             without or with corticosteroids ≤10 mg/day), and that they are stable on the day of&#xD;
             inclusion.&#xD;
&#xD;
         12. No history of other malignant tumor during the previous 5 years, except for adequately&#xD;
             treated carcinomas (in situ cervical carcinoma, basal cell carcinoma, squamous cell&#xD;
             skin carcinoma) and low grade localized prostate cancer (Gleason &lt;6).&#xD;
&#xD;
         13. Adequate organ function, as demonstrated by laboratory results within 7 days prior to&#xD;
             the first administration of study treatment:&#xD;
&#xD;
               1. Normal hepatic function: bilirubin ≤1.5 x upper limit of normal (ULN), alanine&#xD;
                  aminotransferase (ALAT) and aspartate aminotransferase (ASAT) ≤2.5 x ULN or ≤5 x&#xD;
                  ULN in case of liver metastases&#xD;
&#xD;
               2. Normal renal function: calculated creatinine clearance (CrCl, using local&#xD;
                  formula) of at least 60 mL/min for cisplatin or 45 ml/mn for carboplatin&#xD;
&#xD;
               3. Normal hematological function: absolute neutrophil count ≥1.5 giga/L and/or&#xD;
                  platelets ≥100 giga/L, hemoglobin ≥8 g/dL&#xD;
&#xD;
               4. Normal coagulation function: International Normalized Ratio (INR) or prothrombin&#xD;
                  time ≤1.5 x ULN and activated partial thromboplastin time (aPTT) ≤1.5 x ULN&#xD;
                  unless the patient is receiving anticoagulant therapy.&#xD;
&#xD;
         14. For patients of childbearing potential: use of an adequate method of contraception&#xD;
             during the course of the study through 180 days after the last dose of study treatment&#xD;
             (women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to the first administration of study treatment).&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and the patient's&#xD;
             preferred contraception. For male subjects, male condom or abstinence are acceptable.&#xD;
&#xD;
         15. Signed informed consent to participate in the study&#xD;
&#xD;
         16. Affiliation with or benefit from French social security.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          1. NSCLC with expression of PD-L1 &lt;50%.&#xD;
&#xD;
          2. NSCLC with known activating mutation of EGFR or ALK or ROS-1 translocation.&#xD;
&#xD;
          3. Neuroendocrine tumor. In cases of mixed tumors, if small cell elements are present,&#xD;
             the patient is ineligible.&#xD;
&#xD;
          4. Any previous treatment with immunotherapy regardless of the line of treatment.&#xD;
&#xD;
          5. Before the first dose of study treatment:&#xD;
&#xD;
               1. Has received prior systemic treatment for metastatic disease (chemotherapy or&#xD;
                  targeted therapy).&#xD;
&#xD;
               2. Had major surgery &lt;3 weeks prior to first dose.&#xD;
&#xD;
               3. Received radiation therapy to the lung that is &gt;30 Gy within 6 months of the&#xD;
                  first dose of study treatment.&#xD;
&#xD;
          6. Uncontrolled and untreated superior cava syndrome.&#xD;
&#xD;
          7. Untreated and unstable symptomatic brain metastases.&#xD;
&#xD;
          8. Leptomeningeal disease.&#xD;
&#xD;
          9. Serious concurrent conditions during the previous 6 months (severe or unstable angina&#xD;
             pectoris, coronary or peripheral artery bypass graft of &lt;6 months, class 3 or 4&#xD;
             congestive heart failure, ischemic stroke, grade ≥2 peripheral neuropathy, psychiatric&#xD;
             or neurological disorders that may interfere with the patient's understanding of the&#xD;
             study or with his/her informed consent.&#xD;
&#xD;
         10. Severe or non controlled systemic diseases deemed incompatible with the protocol.&#xD;
&#xD;
         11. Severe infections within 4 weeks prior to inclusion, including, but not limited to,&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia.&#xD;
&#xD;
         12. Other previous or concomitant cancers, with the exception of basal cell carcinoma,&#xD;
             squamous cell skin carcinoma, in situ cervical carcinoma treated, and low grade&#xD;
             localized prostate cancer (Gleason score &lt;6) if appropriately treated, unless the&#xD;
             initial tumor has been diagnosed and definitively treated &gt;5 years prior to the study,&#xD;
             with no signs of relapse.&#xD;
&#xD;
         13. Psychological, family, social, or geographical factors that may interfere with the&#xD;
             monitoring of the patient as defined by the protocol.&#xD;
&#xD;
         14. Any protected person (legal person protected by legal protection [guardianship,&#xD;
             tutorship], person deprived of liberty, pregnant woman, breastfeeding woman, and&#xD;
             minor).&#xD;
&#xD;
         15. Patients who participated in other concomitant studies unless observational and&#xD;
             received study therapy or used an investigational device within 4 weeks prior to start&#xD;
             of study treatment.&#xD;
&#xD;
         16. Known or suspected active autoimmune disease requiring an immunosuppressive therapy&#xD;
             during the previous 6 months (corticosteroids or other immunosuppressive treatment).&#xD;
             Any hormone replacement therapy (i.e. thyroxine [T4], insulin, or replacement systemic&#xD;
             corticosteroids for adrenal or pituitary insufficiency, etc.) is not considered an&#xD;
             immunosuppressive treatment and is authorized. Patients with hyperthyroidism or&#xD;
             hypothyroidism who are stable under hormone replacement therapy may also be included.&#xD;
&#xD;
         17. Chronic use of immunosuppressive drugs and/or corticosteroids (&gt;10 mg of prednisone&#xD;
             daily). However, during the 14 days prior to randomization the use of the following is&#xD;
             authorized:&#xD;
&#xD;
               1. Corticosteroids as pre treatment for the administration of chemotherapy and/or&#xD;
                  for allergies or type IV hypersensitivity responses&#xD;
&#xD;
               2. Daily prednisone (≤10 mg) as replacement therapy&#xD;
&#xD;
               3. Inhaled or topical steroids.&#xD;
&#xD;
         18. Live-virus vaccination within 30 days of planned start of study treatment (seasonal&#xD;
             flu vaccines that do not contain live virus are permitted).&#xD;
&#xD;
         19. Previous allogenic tissue or organ transplant.&#xD;
&#xD;
         20. History of human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody test&#xD;
             results).&#xD;
&#xD;
         21. Active hepatitis B or C.&#xD;
&#xD;
         22. Previous history of interstitial lung disease (ILD) or non infectious pneumonia (other&#xD;
             than chronic obstructive pulmonary disease [COPD]), requiring oral or systemic&#xD;
             steroids, current pneumonia, or anticipated ILD.&#xD;
&#xD;
         23. Known allergies or adverse reactions to the study drugs or hypersensitivity reaction&#xD;
             to treatment with another monoclonal antibody (mAb).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud DESCOURT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie, CHRU Brest, Hôpital Morvan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal DECROISETTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pneumologie, CH Annecy Genevois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos CHOUAID, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Service de pneumologie, CH intercommunal de Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud DESCOURT, MD</last_name>
    <phone>2 98 22 38 27</phone>
    <phone_ext>+33</phone_ext>
    <email>renaud.descourt@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal DECROISETTE, MD</last_name>
    <phone>4 50 63 66 01</phone>
    <phone_ext>+33</phone_ext>
    <email>cdecroisette@ch-annecygenevois.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie BERNARDI</last_name>
      <phone>4 42 33 50 67</phone>
      <phone_ext>+33</phone_ext>
      <email>mbernardi@ch-aix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU AMIENS - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine FRANCOIS</last_name>
      <phone>3 22 45 60 00</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.geraldine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Capucine WILLEMIN</last_name>
      <phone>2 41 35 58 44</phone>
      <phone_ext>+33</phone_ext>
      <email>mariecapucine.willemin@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud DESCOURT, MD</last_name>
      <phone>2 98 22 38 27</phone>
      <phone_ext>+33</phone_ext>
      <email>renaud.descourt@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gilles ROBINET</last_name>
      <email>gilles.robinet@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de lutte contre le cancer - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radj GERVAIS</last_name>
      <phone>2 31 45 50 13</phone>
      <phone_ext>+33</phone_ext>
      <email>RGERVAIS@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chambery</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julian PINSOLLE</last_name>
      <phone>4 79 96 50 86</phone>
      <phone_ext>+33</phone_ext>
      <email>julian.pinsolle@ch-metropole-savoie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Bernard AULIAC</last_name>
      <phone>1 57 02 20 85</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-bernard.auliac@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain VERGNENEGRE</last_name>
      <phone>5 55 05 66 29</phone>
      <phone_ext>+33</phone_ext>
      <email>alain.vergnenegre@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Lorient - Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud PEDRONO</last_name>
      <phone>2 97 06 96 95</phone>
      <phone_ext>+33</phone_ext>
      <email>m.pedrono@ghbs.bzh</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie SWALDUZ</last_name>
      <phone>4 26 55 67 61</phone>
      <phone_ext>+33</phone_ext>
      <email>Aurelie.SWALDUZ@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK</last_name>
      <phone>4 91 22 37 89</phone>
      <phone_ext>+33</phone_ext>
      <email>MADROSZYKA@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT</last_name>
      <phone>4 13 42 72 37</phone>
      <phone_ext>+33</phone_ext>
      <email>j.letreut@hopital-europeen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU MARSEILLE_ Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER</last_name>
      <phone>4 91 96 59 01</phone>
      <phone_ext>+33</phone_ext>
      <email>laurent.greillier@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH MEAUX</name>
      <address>
        <city>Meaux</city>
        <zip>77108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystèle LOCHER</last_name>
      <phone>1 64 35 38 56</phone>
      <phone_ext>+33</phone_ext>
      <email>chlocher@ghef.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie WISLEZ</last_name>
      <phone>1 58 41 30 91</phone>
      <phone_ext>+33</phone_ext>
      <email>marie.wislez@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Annecy-genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal DECROISETTE, MD</last_name>
      <phone>4 50 63 66 03</phone>
      <phone_ext>+33</phone_ext>
      <email>cdecroisette@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORRE</last_name>
      <phone>2 98 52 60 96</phone>
      <phone_ext>+33</phone_ext>
      <email>romain.corre@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU RENNES - Hôpital Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles RICORDEL</last_name>
      <phone>2 99 28 37 38</phone>
      <phone_ext>+33</phone_ext>
      <email>charles.ricordel@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Roche Sur Yon - CHD Les Oudairies</name>
      <address>
        <city>Roche Sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Acya BIZIEUX-THAMINY</last_name>
      <phone>2 51 44 61 64</phone>
      <phone_ext>+33</phone_ext>
      <email>acya.bizieux@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU ROUEN - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian GUISIER</last_name>
      <phone>2 32 88 82 47</phone>
      <phone_ext>+33</phone_ext>
      <email>Florian.Guisier@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH SAINT-BRIEUC - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22023</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Saint Aubin Les Elbeuf</name>
      <address>
        <city>Saint-Aubin-lès-Elbeuf</city>
        <zip>76503</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Alexandre HAUSS</last_name>
      <phone>2 32 82 21 45</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre-alexandre.hauss@chi-elbeuf-louviers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Réunion - Site Félix Guyon</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane MOREAU</last_name>
      <phone>2 62 90 55 70</phone>
      <phone_ext>+33</phone_ext>
      <email>diane.moreau@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion - Groupe Hospitalier Sud</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric HUCHOT</last_name>
      <phone>2 62 71 04 47</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.huchot@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAINT-PRIEST EN JAREZ - Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire TISSOT</last_name>
      <phone>4 91 96 59 01</phone>
      <phone_ext>+33</phone_ext>
      <email>claire.tissot@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland SCHOTT</last_name>
      <phone>3 88 25 24 56</phone>
      <phone_ext>+33</phone_ext>
      <email>r.schott@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Toulon - Saint Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI</last_name>
      <phone>4 83 16 25 03</phone>
      <phone_ext>+33</phone_ext>
      <email>bylicki_olivier@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHITS Toulon sainte musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarisse AUDIGIER- VALETTE</last_name>
      <phone>4 94 14 51 77</phone>
      <phone_ext>+33</phone_ext>
      <email>clarisse.audigier-valette@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Villefranche Sur Saone</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel FALCHERO</last_name>
      <phone>4 74 09 27 23</phone>
      <phone_ext>+33</phone_ext>
      <email>lfalchero@ch-villefranche.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin BESSE</last_name>
      <phone>1 42 11 43 22</phone>
      <phone_ext>+33</phone_ext>
      <email>benjamin.besse@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>PDL1≥50%</keyword>
  <keyword>advanced stage</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Chemotherapy-pembrolizumab combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning five years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

